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Abstract 
 
Objectives 
To describe characteristics and course of a large United Kingdom cohort of children 
with moyamoya from multiple centres, and examine prognostic predictors. 
 
Methods 
Retrospective review of case notes/radiology, with use of logistic regression to 
explore predictors of outcome.  
 
Results 
Eighty-eight children (median presentation age 5.1 years) were included. Thirty-six 
presented with arterial ischaemic stroke (AIS) and 29 with transient ischaemic attack 
(TIA). Eighty had bilateral and eight unilateral carotid circulation disease; 29 patients 
had posterior circulation involvement. Acute infarction was present in 36/176 
hemispheres and chronic infarction in 86/176 hemispheres at the index presentation. 
Sixty-two of 82 with symptomatic presentation had at least one clinical recurrence.  
 
Fifty-five patients were treated surgically with 37 experiencing fewer recurrences 
after surgery. Outcome was categorised as good using the Recovery and 
Recurrence Questionnaire in 39/85 patients. On multivariable analysis presentation 
with TIA (OR= 0.09, 95% CI= 0.02-0.35), headache (OR= 0.10, 95% CI= 0.02-0.58) 
or no symptoms (OR= 0.08, 95% CI= 0.01-0.68) was less likely to predict poor 
outcome than AIS presentation. Posterior circulation involvement predicted poor 
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outcome (OR= 4.22, 95% CI= 1.23-15.53). Surgical revascularisation was not a 
significant predictor of outcome.  
 
Conclusions 
MM is associated with multiple recurrences, progressive arteriopathy and poor 
outcome in half, especially with AIS presentation and posterior circulation 
involvement. Recurrent AIS is rare after surgery. Surgery was not a determinant of 
overall outcome, likely reflecting surgical case selection and presentation clinical 
status.  
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Introduction 
 
Moyamoya (MM) is a cerebrovascular condition characterised angiographically by 
occlusive disease of the terminal internal carotid, anterior or middle cerebral arteries 
(ICA/ACA/MCA) and a network of basal collaterals(1). In Japan and East Asia, where 
MM is most prevalent(2), reported natural history has been of high rates of 
progressive disease, recurrent events and cognitive decline, with major functional 
effects(3–5). However, a recent population screening study in Japan identified many 
asymptomatic cases, suggesting that natural history may be more variable(6). As MM 
is rare outside East Asia(7,8) the disease phenotype has not been well characterised 
elsewhere. Available data suggests a more benign disease course and a lower rate 
of cerebral haemorrhage(9,10)  Most non-Eastern series are subject to significant 
ascertainment bias, with potential over-reporting of severe presentations. The 
diagnostic label of MM is applied variably to cases of bilateral cerebral occlusive 
arteriopathy but specific radiological features are likely to be important in defining 
clinically important subgroups(11).  
 
Surgical revascularisation is widely offered in MM to prevent ischaemic symptoms. 
Although symptom reduction and good functional outcomes are reported both in 
Eastern patients(12,13) and others(14–16), uncertainty regarding natural history and 
prognostic predictors makes it difficult to identify optimal surgical candidates and to 
objectively evaluate the efficacy of surgery.  
 
Here, we describe the clinical and radiological features, course, outcomes, and their 
predictors in an eleven-year cohort of UK paediatric moyamoya patients.     
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Methods 
 
Children (aged up to 18 years) with a new diagnosis of MM (whether symptomatic or 
incidentally identified, and whether idiopathic (MM disease) or secondary to a 
recognised association (MM syndrome)) between 1 January 2004 and 31 December 
2014 were eligible for inclusion. All cases were considered as a single group, with 
separate consideration of the influence of a recognised risk factor for MM. MM was 
defined as stenosis or occlusion of the TICA and/or MCA and/or ACA with basal 
collaterals (CASCADE category 3A (bilateral) & 2A (unilateral)(17)). Intracranial 
occlusive arteriopathy without basal collaterals (unilateral (CASCADE 2B,C,D) or 
bilateral (CASCADE 3B,C) were excluded – to enable comparison with published 
series. Angiographic features were confirmed by review of imaging (VG/DS) in all 
cases.  
 
Patients were identified from two sources:  
 
(i) the multidisciplinary MM clinic  at Great Ormond Street Hospital for Children 
(GOSH) that accepts UK-wide referrals for diagnostic opinions or evaluation for 
revascularisation surgery. Patients were evaluated uniformly with clinical 
assessment, brain magnetic resonance imaging and angiography (MRI/A) and 
catheter angiography (CA). Surgery was considered in patients with a demonstrable 
tendency to recurrence - i.e. more than one clinical or radiological event - although 
ultimately surgical decisions were made on a case-by-case basis.  The hospital audit 
department confirmed that ethical approval was not required for review of existing 
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clinical and radiological material that was obtained as part of standard clinical care in 
these patients. 
 
(ii) the British Paediatric Moyamoya Study group. A local investigator (LI) was 
identified at each paediatric regional neuroscience centre in the UK. Cases were 
notified by them and additional cases sought via the British Paediatric Neurology 
Surveillance group (BPNSU), a national collaboration of UK paediatric neurologists 
who receive a monthly e-mail requesting notification of rare conditions under study. 
The study was reviewed and approved by the London and Bloomsbury research 
ethics committee (ref (14/LO/0323) and opened in 17 sites, with local governance 
approval at each site. Two regional centres did not open as study sites as it was 
anticipated (and confirmed at study closure) that cases were unlikely to be seen. The 
LIs sought assent from patients; the GOSH team obtained informed consent. Clinical 
data was obtained from parental interview by telephone. Relevant imaging studies 
were electronically transferred (with consent) to GOSH and centrally reviewed.  
 
Data on patient demographics, co-morbidities, family history, clinical presentation, 
recurrent events, treatment and outcomes was obtained from clinic letters, case 
notes or parent interview.  
 
Demographic data included age, sex, family history, comorbidities and other 
diagnoses.  Presentation was categorised as transient ischaemic attack (TIA), 
arterial ischaemic stroke (AIS), cerebral haemorrhage, seizures, headache, chorea 
or other (including silent infarcts). All medical and surgical interventions were noted. 
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Recurrent events were categorised as for presenting symptoms and also in terms of 
temporal relationship to any surgical intervention.  
 
Scans were reviewed to confirm study eligibility. Brain MRI findings were 
summarized according to infarct distribution (unilateral/bilateral) and infarct timing 
(acute/established). For serial imaging studies, the first and most recent scans were 
compared to ascertain identify new changes. Cerebrovascular findings were 
summarized from MRA or CA. Initial findings were categorised according to whether 
the disease was unilateral or bilateral, and for posterior circulation involvement. First 
and most recent cerebrovascular imaging was compared to ascertain progression of 
arteriopathy (defined as more extensive abnormality of previously abnormal artery or 
involvement of a new artery). 
 
Clinical outcome was evaluated from case notes or parent interview using a 
combination of the modified Rankin Scale (mRS) and the type of school attended 
(mainstream or needing educational support). This has been previously validated for 
evaluation of outcome after childhood AIS(18) and confirmed to have good 
concordance with the Paediatric Stroke Outcome Measure (PSOM), a commonly 
used childhood stroke outcome scale. Good outcome was defined as a mRS ≤ 2 and 
attendance at mainstream school without additional support; poor outcome was 
defined as a mRS ≥ 3 and/or attendance at special school or mainstream school with 
additional support(18).  
 
Statistical analysis was undertaken using SPSS Statistics v22. Univariable logistic 
regression was used to explore the relationship between clinical/radiological 
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variables and outcome. Significant and clinically important variables were then 
entered into a multivariable model. Predictors which did not significantly alter the 
odds ratios were removed to create the final model.  
 
Results 
 
Patient demographics 
Figure 1 summarises the identification pathway for the patients whose data is 
reported here. Eighty-eight children were included (56 female). Ethnicity was White 
(57%), Black (19%) and South Asian (15%); no patients were East Asian. Thirty-one 
(35%) had a risk factor known to be associated with MM (MM syndrome, table 1). 
Eight had a family history of MM, including sibling pairs from two families, without an 
identified genetic or syndromic diagnosis. 
 
Initial clinical and radiological findings 
Median age at initial presentation was 5.1 years (range= 0.3-16.4 years), with most 
children presenting during primary school years. Patients presented predominantly 
with ischaemic symptoms, 36 (40.9%) with AIS and 29 (33.0%) with TIA. Other 
presentations included cerebral haemorrhage in one case, seizures in four cases, 
headache in ten cases and hemi-chorea in two cases. Six children were 
asymptomatic at diagnosis and had MRI scans for other indications such as sickle 
cell disease and microcephalic osteodysplastic primordial dwarfism type II.  
 
Initial radiological findings 
All patients had brain MRI at presentation that showed acute focal infarction in 
36/176 hemispheres in the 88 children. Eighty-six hemispheres additionally had 
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evidence of chronic ischaemic injury on the index MRI, indicating previous, clinically 
silent, ischaemic damage. Magnetic resonance angiography of the circle of Willis 
showed bilateral arteriopathy in 80 cases (CASCADE 3A) and unilateral disease in 
the remaining 8 (CASCADE 2A). The findings from the initial brain MRI and MRA are 
schematically summarised in in figure 2. 
 
Subsequent course 
The patients’ clinico-radiological course is summarised in table 2, divided into those 
that had had surgical revascularisation and those that did not. Surgical 
revascularisation was undertaken in 55 children (unilateral surgery= 19, bilateral 
surgery= 36), 44 with recurrent clinical symptoms and a further seven who had had 
further cerebral infarction on re-imaging. The specific surgical indication was not 
available in the remaining four as this was not apparent from parental interview. The 
median age at first surgery was 6.3 years (range= 1.3-17.6 years), a median of 1.1 
years (range= 0.1-7.4 years) from initial presentation. The 45 patients surgically 
treated at GOSH had pial synangiosis; procedural details in the others could not be 
obtained from parental interview. One patient with bilateral disease treated surgically 
with pial synangiosis went on to have multiple burr holes due to refractory ischaemic 
symptoms, with some clinical improvement.  
 
Ten patients (18%) had a neurological event within one week of surgery; seven had 
a TIA (of which five related to the surgical hemisphere), one had a cerebral 
haemorrhage (whilst anticoagulated) and two had AIS. The latter three patients 
experienced new neurological deficits related to these events.  
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Seventy-three (83.0%) patients were on antiplatelet therapy (73 on aspirin; one also 
on clopidogrel and one also on dipyridamole). Six (6.8%) patients were on 
anticoagulants.   
 
Median duration of follow-up was 43 months (0.3-135 months): 47 months in the 
surgical group (2-145 months) and 36 months in the non-surgical group (0.3-109 
months). In total, 62 of the 82 patients with symptomatic presentation had at least 
one recurrent event (40 TIA, 28 AIS (not mutually exclusive)). Of the six who had 
been asymptomatic at the time of initial diagnosis two went on to have TIAs. Of the 
36 patients with initial AIS, 17 went on to have recurrent AIS (of whom 3 also had 
recurrent TIA) and 7 had subsequent TIA; 12 children in this group did not have 
further recurrences after the index AIS. Fifty-two patients had more than one 
recurrent event.  
 
Thirty-three patients of the 55 in the surgical group had clinical recurrence of 
cerebral ischaemia (29 TIA, four AIS) after surgical revascularisation (including the 
post-operative events described above). However, 37/55 of the surgical group had 
an absolute reduction in the frequency or severity of recurrences compared with pre-
operative levels.  
 
Fifty-seven patients (18 non-surgical and 39 surgical group) had repeat brain 
imaging, undertaken 0.2-10.2 years from initial diagnosis. Comparing initial and final 
MRI and MRA, 18 patients had evidence of new ischaemic damage on MRI, a 
median of 3.6 years from presentation, including new brain injury identified after 
surgical revascularisation in 7 cases. This was usually in deep grey structures or 
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white matter – i.e. relatively deep in the brain. Five of the seven who developed new 
infarcts after surgery had had a corresponding clinical event. Twenty-one patients 
had further transient clinical events without new infarcts on re-imaging. 
 
Twenty-seven patients had evidence of progressive arteriopathy (including 23 who 
had had surgery); however, the timing of arteriopathy progression could not be 
precisely evaluated in relation to surgery due to variable imaging time points. It is of 
note that surgery patients were significantly more likely to have progressive 
arteriopathy (23/39 compared with 4/18, p = 0.01) – suggesting patients with 
potentially more aggressive disease are being selected for surgery. It is difficult to 
meaningfully comment on the rates of new infarcts in the patients imaged serially, 
either pre- or post-operatively as these represent a subset, without any systematic 
imaging schedule. 
 
Outcomes 
One child died secondary to cerebral haemorrhage. Outcome data was available for 
85 survivors; the remaining three were pre-schoolers who could not be assigned a 
mRS score. Outcome was categorised as good in 39 (44.3%) patients. Interestingly 
of patients who had been managed in centres other than GOSH, outcome was 
classed as good in two patients and poor in 14 patients (compared with 37 good and 
32 poor in the GOSH cohort; Fisher’s exact text p<0.01) – as will be discussed, the 
reasons for this are likely to be complex. A breakdown of the mRS, type of school 
attended and overall outcomes in the surgical and non-surgical patients is shown in 
table e-1.  
 
Prognostic predictors 
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Predictors of poor outcome are shown in tables e-2 (univariable) and 3 
(multivariable). In univariable analysis children with non-AIS presentation were 
significantly less likely to have a poor outcome; presence of a risk factor associated 
with MM was also a predictor of poor outcome (OR= 6.00, 95% CI= 2.11-17.06).  
 
Multivariable analysis confirmed that presentation with TIA, headache or no 
symptoms was significantly associated with a lower chance of poor outcome than 
AIS presentation. Having controlled for other variables, posterior cerebral circulation 
involvement was also a predictor of poor outcome; however, having a MM risk factor 
(MM syndrome) was no longer significant.  
 
 
Discussion 
 
Here we present data from a recent multi-centre UK cohort of childhood MM 
confirming frequent ischaemic presentations. Approximately half of patients had a 
good neurological outcome – although it is difficult to dissect the contribution of 
surgical revascularisation as surgical cases were selected on the basis of their 
presumed higher risk for progression. Adverse prognostic features were AIS 
presentation and posterior circulation involvement.  
 
In order to enable comparison to other, particularly East Asian, series our cohort was 
selected according to strict radiological criteria. We may have inadvertently excluded 
early cases of bilateral MM (prior collateral development, CASCADE 3B) but we felt 
radiological homogeneity was important as, in a previous study of young children 
with bilateral cerebral arteriopathies, disease trajectory was different in those with 
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and without collaterals11. There may also be cases of unilateral cerebral arteriopathy 
without collaterals (CASCADE 2B) that represent early cases of unilateral MM. 
Without a robust disease biomarker for MM, there is risk of both under- and over-
ascertainment but, by applying consistent and transparent radiological criteria, we 
aimed to identify a relatively uniform group.  
 
The lack of serial imaging in a proportion of patients reflects the long ascertainment 
period (with variations in practice), differences in approach between centres and 
short follow-up in a small number of cases. We may have under-ascertained 
clinically silent progression of brain injury and arteriopathy as this was apparent in 
some re-imaged patients. However, the clinical significance of asymptomatic disease 
progression is unclear, especially since arteriopathy progression appeared to 
continue even after surgery. We have not used progressive radiological change as 
an outcome parameter and therefore this issue should not alter our conclusions. 
 
While it would be incorrect to present this as an epidemiological study, we have 
attempted to reduce ascertainment bias by involving a national network of paediatric 
neurologists. Paediatric neuroscience centres in the UK generally work in a 
multidisciplinary model and it would be extremely unusual for patients to present to 
other professionals (e.g. neurosurgeons) without paediatric neurology involvement. 
Thus, it is likely that the vast majority of UK paediatric cases UK between 2004 and 
2014 were identified. We had a high rate of enrolment but recognise that 
ascertainment was likely incomplete. For example, many children with sickle cell 
disease and cerebrovascular disease are managed by paediatric haematologists not 
neurologists. There appear to be differences in clinical outcomes between children 
 Ganesan 
 
17 
seen in GOSH, with a higher proportion of these with good outcomes. The reasons 
for this are likely to be diverse and impossible to tease out – but this observation 
suggests that the potential referral centre bias for more severe presentations did not 
hold true in this cohort. Comparing the groups, this difference seems more likely to 
be due to clinical state at diagnosis, rather than any difference in management 
approach. Thus, with the reservations discussed we feel this study presents useful 
data on a large non-Eastern paediatric cohort. 
 
The majority of patients in our study presented with ischaemic events, consistent 
with findings from both East Asian and Western studies(16,19–21). Posterior cerebral 
circulation involvement is common in MM(22,23) and, unsurprisingly an adverse 
prognostic feature – presumably due to impairment of an alternate source of 
collateral circulation. Also unsurprising is the relationship between AIS and poor 
outcome as these children have irreversible brain injury at presentation. Whilst the 
apparent adverse effect of co-morbidities on outcome appeared to be accounted for 
by presentation and posterior circulation involvement, the high rate of these in MM 
pose an additional challenge to dissecting out the relative effects of the disease, its 
treatment, and additional factors.  
 
Whilst the mRS/school type assessment has been shown to relate well to the 
Paediatric Stroke Outcome Measure(24) we acknowledge that it is really only a crude 
assessment of function, with a major motor bias. Young age and co-morbidities are 
also expose the limitation of this outcome assessment. These limitations mean that 
there is a likely underestimate of “good” outcomes. Naturally prospective studies 
should aim to be more comprehensive and to use standardised measures, ideally 
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within the International Classification of Functioning, Disability and Health (ICF) 
framework. 
 
The main aim of surgical revascularization in MM is to prevent AIS, and only four of 
the fifty-five surgical patients experienced post-surgery AIS and three quarters of 
patients with recurrent events prior to surgery experienced a reduction in the 
frequency or severity of these, consistent with previous UK, US and Japanese 
studies(12,14,15). It is difficult compare studies as many only report reductions in TIA 
symptoms, while our study reports reductions in all types of recurrences. In addition, 
MRI identified new infarcts in seven patients after surgery, suggesting that, while 
surgery appears successful in preventing clinical recurrence, it may not prevent 
radiological disease progression, as was also evident by the rates of arteriopathy 
progression observed. 
 
We were interested to observe that outcome was categorised as poor in over half of 
patients who underwent surgical revascularization, in contrast to the higher 
proportions of favourable outcomes (using different measures) reported in previous 
studies(16,25). The possible reasons behind this are complex and we emphasise that 
the surgery and non-surgery groups are not inherently comparable, nor randomly 
allocated. Potential explanations are that surgery does not influence the natural 
history of MM, thus its effects on outcome are limited. Alternatively, patients who 
underwent surgery might have had poor pre-operative functional and cognitive 
abilities due to established brain injury, such that post-operative outcome would 
continue to be categorised as poor. Given that many patients presented with AIS this 
is an important consideration but unfortunately in our retrospective study we were 
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not able to ascertain pre-operative functional status and naturally accept this as a 
limitation. A further reason might be that all non-surgical patients were accurately 
predicted to have a good outcome – which was why they were not offered surgery. It 
is difficult to draw any wider conclusions from these data but they do challenge the 
concept that surgery is mandatory in all MM patients. From an ethical and logistic 
perspective, it seems very unlikely that there will ever be a trial of surgical 
revascularization in MM, and unclear on what basis one would randomise patients. 
However, data such as those presented here could form the basis of expert 
consensus, to standardise management and enable prospective critical appraisal of 
practice. 
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Tables and figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source of patient identification 
Figure 1: Source of patient identification; *8 patients were ineligible as they did not 
meet age/study time period criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BPNSU notifications n = 31 
Potentially eligible* n = 23  
Consented and interviewed n = 17  GOSH MM clinic n = 71  
Total cohort n = 88  
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Summary of the distribution of arterial disease and brain infarcts 
Figure 2: A schematic of the Circle of Willis showing the major cerebral arteries, 
summarising the distribution of arterial disease and of brain infarcts. The number of 
hemispheres that went on to be treated by surgical revascularisation is also 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Involvement of the right 
anterior cerebral circulation: 
86 hemispheres  
Involvement of the left 
anterior cerebral circulation: 
82 hemispheres  
Involvement of the posterior 
cerebral circulation: 
29 (33.0%) patients 
Right hemisphere 
Total infarcts:  
55 hemispheres (16 acute, 45 
chronic) 
 
Right revascularisation  
48 hemispheres 
Left hemisphere 
Total infarcts:  
55 hemispheres (20 acute, 41 
chronic) 
 
Left revascularisation 
43 hemispheres 
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Comorbidity  Number of patients  
Down syndrome 14 
Sickle cell disease 11 
Neurofibromatosis type I 3 
Congenital heart disease  17 
Renal/renovascular disease 5 
Cranial radiotherapy/proton beam therapy 3 
Table 1: Risk factors and co-morbidities of the patient cohort.   
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Clinico-radiological 
feature 
Number of surgical patients (n=55) Number of non-
surgical 
patients (n=33) 
Preoperative Postoperative 
Recurrent events 44 33 18 
Headache 21 15 14 
Vascular disease 
progression 
Total= 23/39 re-imaged patients 4/18 re-imaged 
patients 
New infarcts 8/39 re-imaged 
patients 
7/39 re-imaged 
patients 
3/18 re-imaged 
patients 
Table 2: Table of the clinico-radiological features of the cohort. 
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Predictor Odds ratio (95% CI) p value 
Initial presentation 
AIS (reference category) 
TIA 
Headache 
Chorea 
Cerebral haemorrhage 
Seizure 
Asymptomatic 
 
 
0.09 (0.02-0.35) 
0.10 (0.02-0.58) 
Undefined (n = 2) 
Undefined (n = 1) 
0.50 (0.04-6.56) 
0.08 (0.01-0.68) 
 
 
0.001 
0.010 
NA 
NA 
0.593 
0.021 
Posterior cerebral 
circulation involvement 
4.22 (1.23-15.53) 0.022 
Moyamoya risk factor* 2.45 (0.64-9.36) 0.189 
*risk factors include Down syndrome, neurofibromatosis type I, sickle cell disease 
and cranial radiotherapy/proton beam therapy 
Table 3: Multivariable analysis of clinical and radiological predictors of poor 
outcome. Significant findings are shown in bold.   
 
 
 
 
 
 
 
 
